- Home
- CLNN vs ANTX Comparison
CLNN vs ANTX Comparison
Compare CLNN & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLNN
- ANTX
- Stock Information
- Founded
- CLNN 2012
- ANTX 2017
- Country
- CLNN United States
- ANTX United States
- Employees
- CLNN N/A
- ANTX N/A
- Industry
- CLNN Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- CLNN Health Care
- ANTX Health Care
- Exchange
- CLNN Nasdaq
- ANTX Nasdaq
- Market Cap
- CLNN 37.7M
- ANTX 37.6M
- IPO Year
- CLNN N/A
- ANTX 2022
- Fundamental
- Price
- CLNN $4.37
- ANTX $1.41
- Analyst Decision
- CLNN Strong Buy
- ANTX Hold
- Analyst Count
- CLNN 4
- ANTX 5
- Target Price
- CLNN $55.25
- ANTX $3.50
- AVG Volume (30 Days)
- CLNN 42.3K
- ANTX 168.1K
- Earning Date
- CLNN 05-07-2025
- ANTX 03-27-2025
- Dividend Yield
- CLNN N/A
- ANTX N/A
- EPS Growth
- CLNN N/A
- ANTX N/A
- EPS
- CLNN N/A
- ANTX N/A
- Revenue
- CLNN $421,000.00
- ANTX N/A
- Revenue This Year
- CLNN N/A
- ANTX N/A
- Revenue Next Year
- CLNN N/A
- ANTX N/A
- P/E Ratio
- CLNN N/A
- ANTX N/A
- Revenue Growth
- CLNN N/A
- ANTX N/A
- 52 Week Low
- CLNN $3.82
- ANTX $0.87
- 52 Week High
- CLNN $9.20
- ANTX $3.88
- Technical
- Relative Strength Index (RSI)
- CLNN 45.51
- ANTX 72.16
- Support Level
- CLNN $4.25
- ANTX $1.09
- Resistance Level
- CLNN $4.60
- ANTX $1.39
- Average True Range (ATR)
- CLNN 0.32
- ANTX 0.06
- MACD
- CLNN 0.01
- ANTX 0.03
- Stochastic Oscillator
- CLNN 46.67
- ANTX 94.20
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.